Literature DB >> 28097325

Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.

Maria L Lindenberg1, Baris Turkbey1, Esther Mena1, Peter L Choyke1.   

Abstract

IMPORTANCE: Prostate cancer is the second leading cause of cancer deaths in US men. The course of prostate cancer is highly variable, and timely and accurate detection of clinically significant cancer is critical in positively affecting outcomes. OBSERVATIONS: Molecular imaging methods and magnetic resonance imaging (MRI) are the most promising new developments for prostate tumor visualization. While the benefits of MRI are many, positron emission tomography (PET) radiotracers are still available only as research tools. CONCLUSIONS AND RELEVANCE: The current research-based evidence on PET imaging has demonstrated encouraging potential in the initial diagnosis and detection of recurrence and metastases of prostate cancer.

Entities:  

Mesh:

Year:  2017        PMID: 28097325     DOI: 10.1001/jamaoncol.2016.5840

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  17 in total

1.  PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Authors:  Mariya Shapovalova; John K Lee; Yingming Li; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Cancer Res       Date:  2019-09-17       Impact factor: 12.701

2.  Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

Authors:  Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Clin Cancer Res       Date:  2019-11-15       Impact factor: 12.531

3.  Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.

Authors:  Katelyn M Atkins; Ming-Hui Chen; Jing Wu; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff; Eric J Small; Anthony V D'Amico
Journal:  Cancer       Date:  2017-12-20       Impact factor: 6.860

Review 4.  Recent Advancements in CT and MR Imaging of Prostate Cancer.

Authors:  Asha Daryanani; Baris Turkbey
Journal:  Semin Nucl Med       Date:  2021-12-18       Impact factor: 4.802

Review 5.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 6.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Radiologe       Date:  2018-03       Impact factor: 0.635

7.  Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.

Authors:  Albertus W Hensbergen; Tessa Buckle; Danny M van Willigen; Margret Schottelius; Mick M Welling; Felicia A van der Wijk; Tobias Maurer; Henk G van der Poel; Gabri van der Pluijm; Wytske M van Weerden; Hans-Jürgen Wester; Fijs W B van Leeuwen
Journal:  J Nucl Med       Date:  2019-09-03       Impact factor: 10.057

8.  Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.

Authors:  Hallie M Hintz; Joseph P Gallant; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Aaron M LeBeau
Journal:  Clin Cancer Res       Date:  2020-07-07       Impact factor: 12.531

Review 9.  Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers.

Authors:  Zitong Yang; Qinchen Li; Xiangyi Zheng; Liping Xie
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

10.  Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer-Reply.

Authors:  Liza Lindenberg; Baris Turkbey; Peter Choyke
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.